Cargando…

Systematic Review of Single-Agent vs. Multi-Agent Chemotherapy for Advanced Pancreatic Adenocarcinoma in Elderly vs. Younger Patients

SIMPLE SUMMARY: Pancreatic adenocarcinoma is an aggressive tumour with a high mortality, often diagnosed at advanced stages. The current standard of care for first-line therapy is multi-agent FOLFIRINOX or gemcitabine plus nab-Paclitaxel. Pancreatic adenocarcinoma predominantly effects the elderly p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Alison, Nagrial, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136963/ https://www.ncbi.nlm.nih.gov/pubmed/37190218 http://dx.doi.org/10.3390/cancers15082289

Ejemplares similares

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.
por: Fraser, S. C., et al.
Publicado: (1993)

Nutraceuticals as Supportive Therapeutic Agents in Diabetes and Pancreatic Ductal Adenocarcinoma: A Systematic Review
por: Mikolaskova, Iveta, et al.
Publicado: (2023)

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
por: Dixon, A. R., et al.
Publicado: (1992)

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
por: Cardoso, Fatima, et al.
Publicado: (2009)

Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Christenson, Eric S., et al.
Publicado: (2022)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials
por: Chen, Zhouqing, et al.
Publicado: (2018)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
por: Prince, H Miles, et al.
Publicado: (2007)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers
por: Huang, Chunyue, et al.
Publicado: (2019)

Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer
por: Kishan, Amar, et al.
Publicado: (2016)

A meta-analysis and systematic review of single vs. multimodal neuroimaging techniques in the classification of psychosis
por: Porter, Alexis, et al.
Publicado: (2023)

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003)

Traditional vs. Energetic and Perchlorate vs. “Green”: A Comparative Study of the Choice of Binders and Oxidising Agents
por: Lysien, Kinga, et al.
Publicado: (2023)

Safety of parathyroidectomy in older vs. younger patients with primary hyperparathyroidism
por: Mueller, Marlena, et al.
Publicado: (2021)

Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2014)

Moral Judgments of Human vs. AI Agents in Moral Dilemmas
por: Zhang, Yuyan, et al.
Publicado: (2023)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
por: Biagi, James J., et al.
Publicado: (2023)

Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
por: Shafagati, Nazila, et al.
Publicado: (2022)

Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study
por: Fiorentini, Giammaria, et al.
Publicado: (2023)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
por: Ross, P.J., et al.
Publicado: (2021)

Elderly vs Older
por: McCormick, William
Publicado: (1997)

Adjuvant chemotherapy in elderly patients with pancreatic cancer
por: Nagrial, A M, et al.
Publicado: (2014)

Double‐vs single‐balloon catheter for induction of labor: Systematic review and individual participant data meta‐analysis
por: Peel, Morgan D., et al.
Publicado: (2023)

The Association of Physical (in)Activity with Mental Health. Differences between Elder and Younger Populations: A Systematic Literature Review
por: Maynou, Laia, et al.
Publicado: (2021)

Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma
por: Topal, Halit, et al.
Publicado: (2022)

Novel agents for advanced pancreatic cancer
por: Akinleye, Akintunde, et al.
Publicado: (2015)

SonoVue(®) vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma?
por: Kotopoulis, Spiros, et al.
Publicado: (2022)

LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution
por: Zhang, Miaozun, et al.
Publicado: (2015)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)

A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
por: Thakar, Manjusha, et al.
Publicado: (2018)

Systemic exposure to intracameral vs topical mydriatic agents: in cataract surgery
por: Guell, Jose, et al.
Publicado: (2019)

Comparison of perioperative outcomes in elderly (age ≧ 75 years) vs. younger men undergoing robot-assisted radical prostatectomy
por: Yamada, Yuta, et al.
Publicado: (2020)

18 Comparison of Topical Agents for Eschar Removal in Porcine Model: Bromelain-enriched vs. Traditional Collagenase Agents
por: Singer, Adam, et al.
Publicado: (2022)

Advances on Practical Applications of Agents and Multi-Agent Systems: 10th International Conference on Practical Applications of Agents and Multi-Agent Systems
por: Demazeau, Yves, et al.
Publicado: (2012)

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
por: Shek, Dmitrii, et al.
Publicado: (2021)

The sitting vs standing spine()
por: Tsagkaris, Christos, et al.
Publicado: (2022)

Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
por: Thakar, Manjusha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7puskfns4u5hf5bf370nnf4931